Overview
- Multiple outlets report emerging agreements to sell the lowest doses of GLP‑1 weight‑loss drugs for about $149 per month, with some reporting Eli Lilly’s starting Zepbound dose at $299.
- In exchange, Medicare would cover the drugs for some beneficiaries, and several reports indicate Medicaid coverage could also be part of the arrangements.
- The discounts are expected to be offered through the TrumpRx platform, with a White House announcement reported as possible as soon as Thursday.
- Eli Lilly and Novo Nordisk say they are in discussions without disclosing terms, while White House officials caution that unannounced deals should be treated as speculative.
- The talks are linked to a CMS innovation center pilot to cap costs for some Medicare patients, and Novo Nordisk lowered its full‑year outlook citing intensifying competition and pricing pressure.